Sandra Vukusic

Faculté De Médecine Lyon Est
Lyon, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 240 publications

Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for multiple sclerosis: A report of three cases.

Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for multiple sclerosis: A report of three cases.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 04, 2026

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Journal: Annals of clinical and translational neurology
Published: June 12, 2026

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 02, 2026

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Journal: Neurology
Published: May 29, 2026

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Journal: Neurology
Published: May 22, 2026

Updated French OFSEP recommendations for multiple sclerosis MRI: alignment with the 2024 McDonald criteria.

Updated French OFSEP recommendations for multiple sclerosis MRI: alignment with the 2024 McDonald criteria.

Journal: Journal of neuroradiology = Journal de neuroradiologie
Published: May 13, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology
Published: May 05, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 28, 2026

External validation of KFLC index threshold for multiple sclerosis diagnosis in a French cohort.

External validation of KFLC index threshold for multiple sclerosis diagnosis in a French cohort.

Journal: Journal of neurology
Published: April 28, 2026

French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder.

French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder.

Journal: Revue neurologique
Published: April 10, 2026

Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.

Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 05, 2026

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.

Journal: Neurology
Published: April 01, 2026
Showing 1-12 of 240

Last Updated: 09/26/2026